Market Data graphic

Life Sciences

You are here

The Life Sciences sector includes companies involved in biopharmaceuticals, medical manufacturing and distribution, and bio products.

Life sciences companies listed on CSE

Alpha Cognition Inc. is a pre-NDA, biopharmaceutical company dedicated to developing treatments for patients suffering from Alzheimer’s disease and ALS.  ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition and inflammation. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia.  

Ascend Wellness Holdings, Inc. (AWH) is a multi-state operator with assets and partners in Illinois, Maryland, Massachusetts, Michigan, New Jersey, Ohio, and Pennsylvania. AWH owns and operates state-of-the-art cultivation facilities, growing award winning strains and producing a curated selection of products. AWH produces and distributes its in-house Ozone, Ozone Reserve, and Simply Herb branded products.

Asep Medical Holdings Inc. ( is dedicated to addressing the global issue of antibiotic failure by developing novel solutions for significant unmet medical needs in human medicine. The Company is a consolidation of three existing private companies all with technology in advanced development — Sepset Biosciences Inc. (proprietary diagnostic tools to enable the early and timely identification of sepsis), ABT Innovations Inc. (broad-spectrum therapeutic agents to address multi-drug resistant biofilm infections), and SafeCoat Medical Inc. (an antibacterial peptide medical device coating technology). 

Asia Green is an early stage international bio-technology company focused on the development, evaluation, testing, application and, ultimately, supply to the market of proprietary organic hybridization technology and certain products derived from that technology. The core approach of the business is centred on the planting, growth and harvesting of new and valuable strains of hemp and related crops in commercial quantities under the terms of license agreements with InPlanta Biotechnology Ltd., Swysh Inc. and Pathway RX Inc.

Awakn Life Sciences Corp. is a clinical-stage biotechnology company developing medication-assisted treatments for addiction. Awakn has a near-term focus on Alcohol Use Disorder (AUD), a condition affecting approximately 51 million people in the US and key European markets and 285 million people globally for which the current standard of care is inadequate. Our goal is to provide breakthrough therapeutics to addiction sufferers in desperate need and our strategy is focused on commercializing our R&D pipeline across multiple channels.

Ayr is an expanding vertically integrated, U.S. multi-state cannabis operator, focused on delivering the highest quality cannabis products and customer experience throughout its footprint. Based on the belief that everything starts with the quality of the plant, the Company is focused on superior cultivation to grow superior branded cannabis products. Ayr strives to enrich consumers’ experience every day through the wellness and wonder of cannabis.

Ayr’s leadership team brings proven expertise in growing successful businesses through disciplined operational and financial management, and is committed to driving positive impact for customers, employees and the communities they touch. For more information, please visit

Investor Note: In addition to the 99,621,213 Subordinate Voting Shares that are issued and outstanding, there are (a) 3,696,486 shares reserved for issuance pursuant to the conversion rights attached to the Multiple Voting Shares that are issued and outstanding but not listed, (b) 9,638,486 shares reserved for issuance pursuant to the exchange rights attached to the Exchangeable Shares that are issued and outstanding but not listed, and (c) 23,045,965 shares reserved for issuance pursuant to the exercise of currently unlisted warrants that are exercisable at US$2.12 per share. The total number of Subordinate Voting Shares assuming all of the foregoing are exercised or converted, as applicable, and issued would be 136,002,150. The foregoing does not include (i) 2,874,085 shares reserved for issuance pursuant to the exercise of unlisted warrants that are exercisable at US$9.07 per share, or (ii) the Subordinate Voting Shares reserved for issuance pursuant to rights attached to the Restricted Exchangeable Shares granted as equity incentive compensation or rights attached to the Restricted Exchangeable shares that are available under Ayr’s long-term equity incentive plan but that have not been granted. In addition, the 99,621,213 Subordinate Voting Shares noted above includes 645,298 shares that are held by AYR in treasury (under applicable corporate law, they are not entitled to be voted or receive dividends). The above numbers are effective as of February 7, 2024. References to Subordinate Voting Shares include Restricted Voting Shares and Limited Voting Shares, as applicable, as all three classes of share trade under a single stock symbol and CUSIP number.

Each Warrant shall entitle each Warrantholder thereof, upon exercise at any time after the Issue Date and prior to the Expiry Time, to acquire one Subordinate Voting Share upon payment of the Exercise Price of  US$2.12.

See the Warrant Indenture for full details and conditions.

Ayurcann Holdings Corp. is a leading provider of customized post-harvest outsourcing solutions to licensed cannabis producers. Ayurcann Holdings Corp. concentrates on the post-harvest requirements of licensed cannabis producers and other brands looking to enter the cannabis market. Ayurcann Holdings Corp. offers end-to-end full outsourcing solutions including extraction, refinement, formulation, packaging, fulfillment and distribution.

The Exchange has determined that the Issuer has not met the continued listing requirements as set out in CSE Policy 2, Appendix A section 2.9.

Pursuant to Policy 6 section 2.4, the Issuer may not rely on confidential price protection, nor may the Issuer complete any financing without prior Exchange approval.

In accordance with Policy 3, section 5.1, the .X extension is added to the listed securities of Issuers that the Exchange has deemed to be inactive.

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.

BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent for composition and method of use covers treatment of depression, cluster headaches, post-traumatic stress disorder and other neuro-psychiatric and neurological disorders.

BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.

BetterLife also owns a drug candidate for the treatment of viral infections  and is in the process of seeking strategic alternatives for further development.

Contact The Team

How can we help you?

Contact the CSE team to find out more.